Testing effectiveness (Phase 2)Ended earlyNCT04992273
What this trial is testing
COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age
Who this might be right for
COVID-19
Regeneron Pharmaceuticals 7